Dott. M. M. Ciammaichella
Dirigente Medico
Responsabile UAS “Trombosi Venosa Profonda ed Embolia Polmonare”
Responsabile CDF BLSD IRC “Emersan Lateranum”
SC Medicina Interna I° per l'Urgenza
(Direttore: Dott. G. Cerqua)
 

 

TETRALOGY OF FALLOT

 

KEY-WORDS: Tetralogy of Fallot

.

INTRODUCTION
CLINICAL
WORKUP
TREATMENT
MEDICATION
FOLLOW-UP
MISCELLANEOUS
BIBLIOGRAPHY


.

INTRODUCTION

Background: Tetralogy of Fallot (TOF) is a complex of anatomic abnormalities arising from the maldevelopment of the right ventricular infundibulum.

Fallot described the anatomy in 1888 as consisting of a sub-aortic ventricular septal defect, right ventricular infundibular stenosis, an aortic valve positioned to override the right ventricle and right ventricular hypertrophy.

Pathophysiology: There is a wide variation in the basic anatomic morphology, pathophysiology, clinical signs and symptoms and surgical methods of therapy. The pathophysiology is primarily dependent upon the severity of the right ventricular outflow tract obstruction. Right-to-left shunting is typical.

Frequency:

  • In the U.S. : TOF represents approximately 10% of congenital heart disease.

Mortality/Morbidity: The natural history is variable.

  • It is mainly determined by the degree of right ventricular outflow tract obstruction (RVOT).
  • Approximately 25% of untreated patients with TOF and RVOT obstruction die within the first year of life, 40% at 4 years, 70% by 10 years and 95% by 40 years.

Sex: Male greater than female (slightly)

Age: Newborns

 

 


CLINICALPATHOPHYSIOLOGY

History:

  • Cyanosis develops within the first few years of life.
  • Symptoms generally progress secondary to hypertrophy of the infundibular septum.
  • Cyanosis occurs and demands surgical repair.
  • Dyspnea on exertion is common.
  • Squatting is uniquely characteristic of a right-to-left shunt that presents in the exercising child.
  • Hypoxic TET spells are potentially lethal, unpredictable episodes that occur even in non-cyanotic patients with TOF. They can be aborted with relatively simple procedures.
  • The rare patient with TOF may remain marginally and imperceptibly cyanotic or acyanotic and asymptomatic into adult life.
  • Severe cyanosis may present at birth in a patient with TOF and associated pulmonary atresia.
  • Low birth weight
  • Retarded growth

Physical:

  • Right ventricular predominance on palpation
  • Systolic thrill at the lower left sternal border
  • Aortic ejection click
  • Single S2: Pulmonic valve closure not heard
  • Systolic ejection murmur: Varies in intensity inversely with the degree of RVOT obstruction; that is, more cyanotic patients have greater obstruction and a softer murmur.
  • An acyanotic pink TET has a long, loud, systolic murmur with a thrill along the RVOT.
  • Cyanosis and clubbing are variable.
  • Squatting position
  • Scoliosis is common.
  • Retinal engorgement
  • Hemoptysis

Causes:

  • Although there is no specific singular genetic abnormality identified, (e.g., chromosomal abnormalities, as in Trisomy 21), there is undoubtedly a genetic etiology to the family of cardiac malformations known as, conotruncal abnormalities (e.g., double outlet right ventricle, interrupted aortic arch type B, transposition of the great arteries, truncus arteriosus and TOF).
  • Ablation of cells of the neural crest has been shown to reproduce conotruncal malformations.
  • These abnormalities are also associated with the DiGeorge syndrome and branchial arch abnormalities.
  • TOF is frequently associated with the following:
    • Fetal hydantoin syndrome
    • Fetal carbamazepine syndrome
    • Fetal alcohol syndrome
    • Maternal phenylketonuria (PKU) birth defects



WORKUP

Lab Studies:

  • Oximetry and Arterial Blood Gas (ABG)
    • Oxygen saturation is variable, but pH and pCO2 are normal unless the patient is in extremis, such as, during a TET spell.
    • Oximetry is particularly useful in the dark-skinned patient or the anemic patient whose level of cyanosis is not apparent.
    • Cyanosis is not evident until 5.0 mg/dl of reduced hemoglobin is present.
    • A decrease in SVR (systemic vascular resistance) during exercise, bathing or fever will potentiate a right-to-left shunt and cause hypoxemia.
  • Hematology:
    • Prolonged cyanosis causes a reactive polycythemia that will increase the oxygen-carrying capacity.
    • Hyperviscosity and coagulopathy often ensue and are particularly deleterious in patients with a right-to-left intracardiac shunt.
    • Cerebrovascular accident (CVA) and brain abscess are natural corollaries.

Imaging Studies:

  • Chest Roentgenography:
    • Coeur en sabot (boot-shaped heart) secondary to uplifting of the cardiac apex from right ventricular hypertrophy and the absence of a normal main pulmonary artery segment
    • Normal heart size due to the lack of pulmonary blood flow and congestive heart failure
    • Decreased pulmonary vascularity
    • Right atrial enlargement
    • Right aortic arch (25% of patients)
    • May be normal in acyanotic TOF or may resemble findings of small to moderate size VSD with mild RVH, right atrial enlargement and increased pulmonary vascular markings
  • Echocardiography reveals a large VSD with an overriding aorta and variable degrees of right ventricular outflow tract obstruction.
  • Electrocardiogram:
    • Right axis deviation (+120 to +150 degrees)
    • Right or combined ventricular hypertrophy
    • Right atrial hypertrophy

Procedures:

  • Cardiac Catheterization:
    • Assesses pulmonary annulus size and pulmonary arteries
    • Assesses the severity of right ventricular outflow obstruction
    • Locates the position and size of the VSD
    • Rules out possible coronary artery anomalie

 


TREATMENT

Prehospital Care:

  • Any infant with cyanosis and/or respiratory distress requires oxygen.
  • Blow-by O2 (BBO2) is the least objectionable. Use the open-end of a cannula or tube.
  • Permit the baby to remain with the mother or father.
  • Do not provoke the infant by attempting to start an IV, especially if not skilled in pediatric IV starts.
  • An intraosseus insertion could be an immediate lifesaving tool.

Emergency Department Care: The ED physician should be able to recognize and treat a hypercyanotic episode as one of the very few pediatric cardiology emergencies that may present to the ED.

  • Hypoxic TET Spell:

    Hypercyanotic episodes are characterized by paroxysms of hyperpnea, prolonged crying, intense cyanosis and decreased intensity of the murmur of pulmonic stenosis.
    • Mechanism:

      Secondary to infundibular spasm and/or decreased systemic vascular resistance with increased right-to-left shunting at the VSD, resulting in diminished pulmonary blood flow.
    • If left untreated, the following may result in syncope, seizure, CVA or death.
  • Treatment for the acute setting of hypercyanosis includes:
    • Knee-chest position: Place the baby on the mother's shoulder with the knees tucked up underneath. This provides a calming effect, reduces systemic venous return and increases systemic vascular resistance.
    • Oxygen is of limited value since the primary abnormality is reduced pulmonary blood flow.
    • Morphine sulfate, 0.1-0.2 mg/kg SC or IM, may reduce the ventilatory drive and decrease systemic venous return.
    • Phenylephrine (Neo-Synephrine), 0.02 mg/kg IV, is used to increase SVR.
    • Treat acidosis with sodium bicarbonate. It may reduce the respiratory center stimulating effect of acidosis.
    • General anesthesia is a last resort.

 

Consultations: Pediatric cardiology/surgery


.

MEDICATION

The goal of therapy is to reduce the ventilatory drive, decrease systemic venous return and increase peripheral venous return.

Drug Category: Analgesics - These agents are useful in reducing ventilatory drive. Pain control ensures patient comfort and promotes pulmonary toilet. Most analgesics have sedating properties, which are beneficial for patients who have sustained painful skin lesions.

Drug Name

Morphine sulfate - It is the DOC for narcotic analgesia due to its reliable and predictable effects, safety profile, and ease of reversibility with naloxone.

Morphine sulfate administered IV may be dosed in a number of ways and is commonly titrated until the desired effect is obtained.

Pediatric Dose

Administer 0.05-0.2 mg/kg dose prn

The maximum is 15 mg/dose IV

Contraindications

Avoid use in patients with documented hypersensitivity to morphine and those diagnosed with hypotension or a potentially compromised airway where establishing rapid airway control would be difficult.

Interactions

Phenothiazines may antagonize the analgesic effects of opiate agonists. Tricyclic antidepressants, MAO inhibitors and other CNS depressants may potentiate the adverse effects of morphine when used concurrently.

Pregnancy

C - Safety for use during pregnancy has not been established.

Precautions

Avoid using this drug in patients diagnosed with hypotension, respiratory depression, nausea, emesis, constipation, and urinary retention. Exercise caution in patients diagnosed with atrial flutter and other supraventricular tachycardias.

Morphine has vagolytic action and may increase the ventricular response rate.

Drug Category: Alpha-adrenergic agonists - These agents are useful in improving the hemodynamic status by improving myocardial contractility and increasing heart rate, resulting in increased cardiac output. Peripheral resistance is increased by vasoconstriction. Increased cardiac output and increased peripheral resistance increase blood pressure.

Drug Name

Phenylephrine - It is a strong postsynaptic alpha-receptor stimulant with little beta-adrenergic activity that produces vasoconstriction of arterioles in the body. It increases peripheral venous return.

Pediatric Dose

IV bolus: Administer 5-20 mcg/kg/dose q10-15min prn

IV, sc: Administer 0.1 mg/dose q1-2h prn

IV infusion: Administer 0.1-0.5 mcg/kg/min

Contraindications

Avoid use in patients with documented hypersensitivity to this medication or related products and those diagnosed with severe hypertension or ventricular tachycardia.

Interactions

Bretylium may potentiate the action of vasopressors on adrenergic receptors, possibly resulting in arrhythmias.

Guanethidine may increase the pressor response of the direct-acting vasopressors, possibly resulting in severe hypertension.

MAOIs may significantly enhance the adrenergic effects of phenylephrine, and its pressor response may be increased 2- to 3-fold.

Pregnancy

C - Safety for use during pregnancy has not been established.

Precautions

Exercise caution in elderly patients, and those with hyperthyroidism, myocardial disease, bradycardia, partial heart block or severe arteriosclerosis.

In the treatment of hypovolemia, its use is not a substitute for the replacement of blood, fluids and electrolytes, and plasma. These should be restored promptly when loss has occurred.

 

.

FOLLOW-UP

Further Inpatient Care:

  • Palliative surgery:
    • Blalock-Taussig shunt
    • Pott's procedure
    • Waterson's shunt
  • Total surgical correction with patch closure of the VSD and relief of the ventricular outflow obstruction is preferred.

Further Outpatient Care:

  • Good dental hygiene
  • Endocarditis prophylaxis

Complications:

  • Erythrocytosis
  • Brain abscess
  • Acute gouty arthritis
  • Infective endocarditis
  • Cerebrovascular thrombosis
  • Delayed puberty
  • Postoperative Complications:
    • Residual outflow obstruction, VSD and/or pulmonic regurgitation
    • Ventricular arrhythmias, right bundle branch block (RBBB) or left anterior hemiblock
    • Infective bacterial endocarditis

Prognosis:

  • Uniformly fatal if not surgically corrected


MISCELLANEOUS


Special Concerns:

  • Hypoxic TET spells
  • Physical and mental growth impairment
  • Brain abscess and CVA, secondary to the right-to-left shunt
  • Infective endocarditis
  • Polycythemia

Caption:

Cardiac Catheterization findings of Tetralogy of Fallot


Picture Type:

Caption:

Typical preoperative EKG for Tetralogy of Fallot


Picture Type: ECG

Caption:

Typical findings on EKG of Tetralogy of Fallot postoperatively.


Picture Type: ECG

Caption:

Uplifted apex and absence of pulmonary artery segment typifies the "coeur en sabot" boot-shaped heart of Tetralogy of Fallot.


Picture Type:


BIBLIOGRAPHY

  • Fyler DC : Tetralogy of Fallot. Nadas Pediatric Cardiology 1992; 471-493.
  • Kirklin JW, Barrett-Boyes BGF: Ventricular septal defect and pulmonary stenosis or atresia. Cardiac Surgery 1993; 2: 861-1012.
  • Park MK: Tetralogy of Fallot. Pediatric Cardiology or Practitioners 168-175.
  • Silverman NH : Tetralogy of Fallot and related lesions. Pediatric Echocardiography 1993; 195-214.
  • Snider AR, Serwer GA : Defects in cardiac septation. Echocardiography in Pediatric Heart Disease 1990; 150-153.
  • Zuberhuler JH: Tetralogy of Fallot. Heart Disease in Infants, Childrenand Adolescents 1995; II: 998-1026.